IMAPAC recently rounded up its “Corona360 In-Conversation” series of live moderated interviews. It brought together vaccine industry experts in lively, thought-provoking discussions on the challenges and possible solutions in the race to develop a COVID-19 vaccine. While hosting a phenomenal line-up of frontliners in COVID-19 vaccine development efforts, I had the privilege of gleaning insights first-hand.
So, here are some snippets!
“The challenge is that we are competing to have sufficient money, getting access to services, the reagents, suppliers, supplies. The disruption of the supply chain has definitely put a lot of pressure. ”Maria Elena Bottazzi, Associate Dean, National School of Tropical Medicine, Baylor College of Medicine, USA
“A lot of the sites making the reagents are partly shut down. We can’t predict when critical components arrive. Being in a country like Australia, a lot of things have to be imported. Particularly if we are importing cell lines or viruses or anything that they consider requires a special permit. The other thing to add is the need for assays – neutralization assays, T cell assays. The assays have lagged behind a lot of the other work on the vaccines.”Nikolai Petrovsky, Chairman and CSO,Vaxine Pty Ltd, Australia
“Organizations that can assist with that; identify places where trials can be done with high burden are going to be a premium. The funding agencies are starting to realise that the next set of clinical trial sites needs to be developed.”Jerome Kim, Director General of the International Vaccine Institute (IVI), Korea
“The major challenge we faced was the lack of supply and delays in shipment of research reagents. There is less access to animals for pre-clinical studies in India. Hence, we have been sending the products to the US to get the tests done.”Krishna Ella, Chairman & Managing Director, Bharat Biotech, India
“One of the challenges is to have lab assays standardized using the same format in order to compare the results between companies. The biggest challenge is beyond Phase 1, 2 and even 3 and that is the large scale manufacturing capacity that we will face if we want to distribute this vaccine to hundreds of millions of people.”Jean-Louis Excler, Program Director New Initiatives, International Vaccine Institute, Korea
That’s not all!
These are just some of knowledge imparted by our thought leaders. If you would like to re-visit the webcasts or missed out on some – fret not, I have got you covered.
Check out our Corona360 In-Conversation interviews on-demand!
While we are wrapping up the series, you can still get your dose of industry updates on the latest technologies, scientific innovations and more. Head on over to browse our IMAPAC’s Market Intelligence Biopharmaceutical Reports and keep your eyes peeled for further updates on this space.